Taletrectinib Gains Chinese Approval for Advanced ROS1-Positive NSCLC
The decision is supported by results from the phase 2 TRUST-1 trial, which evaluated the safety and efficacy of taletrectinib in ROS1-positive NSCLC.
Related Articles
Welcome! You are invited to join a webinar: Post-ASH 2024 MPN highlights webinar. After registering, you will receive a confirmation email about joining the webinar.
Join us to watch leading experts on MPN present summaries on the most significant abstracts from ASH 2024 followed by interactive panel discussions debating current…
Summer Internship Program (SIP)
Official websites use .gov A.gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock () or…
Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer
Lunresertib plus camonsertib demonstrated efficacy and safety in heavily pretreated endometrial cancer and platinum-resistant ovarian cancer.
Lasofoxifene Aims to Amplify Efficacy of Abemaciclib in ESR1-Mutated ER+/HER2– Metastatic Breast Cancer
Lasofoxifene plus abemaciclib is set to be evaluated in ESR1-mutated ER+/HER2– metastatic breast cancer in the phase 3 ELAINEIII trial.
Survival Outcomes of an Early Intervention Smoking Cessation Treatment After a Cancer Diagnosis
This cohort study evaluates the survival outcomes of currently smoking patients with cancer who entered into a smoking cessation treatment program based on the time…
Divinum opus est sedare dolorem: the power (and beauty) of early palliative care
Mrs A., at the age of 58 years, was referred by her oncologist to the early palliative care (EPC) outpatient ambulatory clinic of our cancer…
Home | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL
Venetoclax-based treatment was associated with poorer outcomes CLL previously treated with a BTK inhibitor and naive to chemotherapy.
CPX-351 vs FLAG-Ida: Post-hoc subgroup analysis of the UK NCRI AML19 trial
During the 66th ASH Annual Meeting and Exposition, Mehta P. presented results from a post-hoc analysis of the UK NCRI AML19 trial evaluating the efficacy…
